<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefdinir: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefdinir: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefdinir: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11830" href="/d/html/11830.html" rel="external">see "Cefdinir: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13125" href="/d/html/13125.html" rel="external">see "Cefdinir: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866229"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Omnicef</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F147198"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Cephalosporin (Third Generation)</li></ul></div>
<div class="block doa drugH1Div" id="F147182"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation: Note: </b>Avoid use in patients with risk factors for <i>Pseudomonas </i>infection or poor outcomes (eg, ≥65 years of age with major comorbidities, FEV<sub>1</sub> &lt;50% predicted, frequent exacerbations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sethi.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sethi.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg twice daily <b>or</b> 600 mg once daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4ad62b3-06e3-44cf-a5e8-d87fc82ac931">Cystitis, acute uncomplicated or acute simple cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to bladder without signs/symptoms of upper tract, prostate, or systemic infection)</b>
<b>(alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use only when preferred agents cannot be used; limited evidence suggests inferior efficacy of oral beta-lactams (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1','lexi-content-ref-21292654'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d31b3c05-03cb-4fcd-8932-e9d1953c0ab8">Odontogenic soft tissue infection, pyogenic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Odontogenic soft tissue infection, pyogenic (initial therapy for mild infection or step-down therapy after parenteral treatment) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients unable to take penicillin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg twice daily in combination with metronidazole; continue until clinical resolution, typically for 7 to 14 days. Use in addition to appropriate surgical management (eg, drainage and/or extraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (alternative agent for mild [nonanaphylactic] penicillin allergy</b>
<b>):</b> Limited data available: <b>Oral:</b> 300 mg twice daily <b>or</b> 600 mg once daily; duration of therapy is 5 to 7 days (mild to moderate infection) <b>or</b> 10 days (severe infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Limb.2021','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Limb.2021','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent for patients with penicillin allergy who are able to tolerate cephalosporins):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-26785402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>300 mg twice daily with clindamycin for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350','lexi-content-ref-Manu.1'])">Ref</a></span>); some experts use as monotherapy when the risk of drug-resistant <i>S. pneumoniae</i> is low (eg, &lt;65 years of age, low endemic resistance, few comorbidities, no recent hospitalization or antibiotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17292580','lexi-content-ref-Patel.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17292580','lexi-content-ref-Patel.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47f1db45-3ef1-4229-9b6c-df5d9de732de">Streptococcal pharyngitis, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A (alternative agent for mild, nonanaphylactic penicillin allergy): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Cephalosporin selection depends on the type of hypersensitivity reaction to penicillin. To avoid the development of resistance, narrower spectrum cephalosporins (eg, cephalexin or cefadroxil) are preferred when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044','lexi-content-ref-Pichichero.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044','lexi-content-ref-Pichichero.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg twice daily for 5 to 10 days <b>or</b> 600 mg once daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pichichero.2018','lexi-content-ref-17908614','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pichichero.2018','lexi-content-ref-17908614','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991726"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>): <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: 300 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~63%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9661010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9661010'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Limited pharmacokinetic data have demonstrated prolonged half-lives and increased serum concentrations in patients undergoing intermittent hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9661010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9661010'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Administer a 300 mg initial dose, followed by 300 mg 3 times per week postdialysis on dialysis days, with an additional 300 mg dose 48 hours into each 72-hour interdialytic period (eg, if dosed Monday/Wednesday/Friday on dialysis days, administer an additional 300 mg dose on Sunday) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Alternatively, pharmacokinetic parameters suggest that 300 mg initially, followed by 300 mg 3 times per week after hemodialysis sessions should be sufficient to meet pharmacokinetic/pharmacodynamic goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Slightly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9748717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9748717'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Limited pharmacokinetic data have demonstrated prolonged half-lives and increased serum concentrations in patients undergoing peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9748717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9748717'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.2013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.2013'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> In general, use of IV antimicrobial therapy or alternative oral therapies with greater bioavailability may be preferred in patients receiving CRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg every 12 hours on PIRRT days; 300 mg every 24 hours on non-PIRRT days (expert opinion). <b>Note:</b> In general, use of IV antimicrobial therapy or alternative oral therapies with greater bioavailability may be preferred in patients receiving PIRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989054"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F147183"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F147192"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13125" href="/d/html/13125.html" rel="external">see "Cefdinir: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: Oral: 14 mg/kg/day in divided doses every 12 to 24 hours; maximum daily dose: 600 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Every-24-hour dosing may be suboptimal, particularly for <i>Streptococcus pneumoniae </i>that are nonsusceptible to penicillin and bacteria with minimum inhibitory concentrations (MICs) ≥0.5 mg/L, based on pharmacokinetic modeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16511381','lexi-content-ref-24187143','lexi-content-ref-11557496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16511381','lexi-content-ref-24187143','lexi-content-ref-11557496'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1701ac17-544f-4206-a37e-0462fd6cd656">Chronic bronchitis, acute bacterial exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic bronchitis, acute bacterial exacerbation:</b> Adolescents: Oral: 300 mg every 12 hours for 5 to 10 days <b>or</b> 600 mg every 24 hours for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (AOM) (alternative agent for nonanaphylactic penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children: Oral: 14 mg/kg/day in divided doses every 12 to 24 hours; maximum daily dose: 600 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-15361722','lexi-content-ref-23039319','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-15361722','lexi-content-ref-23039319','lexi-content-ref-Manu.1'])">Ref</a></span>). For patients with severe or recurrent AOM, tympanic membrane perforation, or who are &lt;2 years of age, treat for 10 days; for patients ≥2 years of age with mild to moderate, nonrecurrent disease without tympanic membrane perforation, shorter durations of 5 to 7 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1'])">Ref</a></span>). <b>Note: </b>Twice-daily dosing is preferred, especially if shorter durations (ie, 5 days) are used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15361722','lexi-content-ref-16117986','lexi-content-ref-24187143','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15361722','lexi-content-ref-16117986','lexi-content-ref-24187143','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (alternative agent): Note:</b> Cefdinir is not active against most strains of penicillin-resistant streptococci and is not approved for treatment of pneumonia caused by penicillin-nonsusceptible <i>S. pneumoniae. </i>Neither pediatric nor adult guidelines recommend cefdinir for patients with pneumonia due to known or suspected <i>S. pneumoniae</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-21880587','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-21880587','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 300 mg every 12 hours for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Durations as short as 5 days, depending on patient response, are recommended in adult community-acquired pneumonia guidelines for patients who are improving clinically (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent for patients with penicillin allergy): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The role of cefdinir in the management of acute bacterial sinusitis is limited; other options are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23796742','lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23796742','lexi-content-ref-22438350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children: Oral: 14 mg/kg/day in divided doses every 12 to 24 hours for 10 days; maximum daily dose: 600 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 300 mg every 12 hours <b>or</b> 600 mg every 24 hours for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd705302-04a3-41a9-ae4b-6351f8cd05b4">Skin and soft tissue infection, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, uncomplicated (alternative agent): Note:</b> Cefdinir is not currently recommended in IDSA guidelines for treatment of skin and soft tissue infection; alternate agents are preferred (eg, first-generation cephalosporins). Additionally, durations shorter than 10 days (eg, 5 days) may be appropriate for uncomplicated infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children: Oral: 7 mg/kg/dose every 12 hours for 10 days; maximum dose: 300 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 300 mg every 12 hours for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="002747a1-d12d-413d-9efb-492e8da1743e">Streptococcus, group A; pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for nonanaphylactic penicillin allergy): </b>
<b>Note:</b> Narrow-spectrum cephalosporins (eg, cephalexin) are preferred over broad-spectrum cephalosporins such as cefdinir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children: Oral: 14 mg/kg/<b>day</b> in divided doses every 12 to 24 hours; maximum daily dose: 600 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Preferred treatment duration is 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044'])">Ref</a></span>), though 5 days may be adequate if cefdinir is dosed twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11144400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11144400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 300 mg every 12 hours <b>or</b> 600 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Preferred treatment duration is 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044'])">Ref</a></span>), though 5 days may be adequate if cefdinir is dosed twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11144400','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11144400','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083963"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥6 months and Children:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: 7 mg/kg/dose every 24 hours; maximum dose: 300 mg/dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: 300 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dialyzable (63%): Infants ≥6 months, Children, and Adolescents: Initial dose: 7 mg/kg/dose (maximum dose: 300 mg) every other day. At the conclusion of each hemodialysis session, an additional dose (7 mg/kg/dose up to 300 mg) should be given. Subsequent doses should be administered every other day.</p></div>
<div class="block dohp drugH1Div" id="F51083968"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56225982"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Antibiotic-associated (non–Clostridioides difficile) diarrhea</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI effects range from antibiotic-associated [non–<i>Clostridioides difficile</i>
<i>]</i>
<b> diarrhea</b> (AAD), <b>nausea</b>, and <b>vomiting</b>. Most cases of AAD are mild and self-limiting. However, <i>Clostridioides difficile</i> may account for as many as &gt;20% of cases in children, adolescents, and adults (discussed separately) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9210677','lexi-content-ref-15823766','lexi-content-ref-27003987','lexi-content-ref-29408016','lexi-content-ref-17385141','lexi-content-ref-15212560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9210677','lexi-content-ref-15823766','lexi-content-ref-27003987','lexi-content-ref-29408016','lexi-content-ref-17385141','lexi-content-ref-15212560'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; antibiotic disruption of indigenous gut microbiota (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32518780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32518780'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; mean time to onset of AAD is 3 to 18 days for adult patients and 2 to 6 days for pediatric patients. The majority of AAD cases occur <i>during</i> (versus after) antibiotic therapy in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27003987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27003987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32518780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32518780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age (pediatric patients &lt;2 years of age and older adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27003987','lexi-content-ref-12827001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27003987','lexi-content-ref-12827001'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Length of hospitalization or ICU stay (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30020891','lexi-content-ref-32518780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30020891','lexi-content-ref-32518780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of proton pump inhibitor use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32518780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32518780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parenteral nutrition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30020891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30020891'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Combinations of antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30020891','lexi-content-ref-31118710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30020891','lexi-content-ref-31118710'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile diarrhea</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection (CDI) has occurred with cefdinir, including <b>
<i>Clostridioides difficile</i> associated diarrhea</b> (CDAD) and <b>
<i>Clostridioides difficile</i> colitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2663814','lexi-content-ref-30921218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2663814','lexi-content-ref-30921218'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; related to cumulative antibiotic exposure. Cefdinir may cause disruption of the intestinal microbiota resulting in the overgrowth of pathogens, such as <i>C. difficile</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-21653301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-21653301'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-21653301','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-21653301','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (third-/fourth-generation cephalosporins among the highest risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospitalization or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors, H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions (immediate and delayed) range from <b>skin rash</b> to rare cases of <b>anaphylaxis</b>. Severe cutaneous adverse reactions (SCARs), including <b>Stevens-Johnson syndrome</b> and <b>toxic epidermal necrolysis</b> have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) are IgE-mediated. Delayed hypersensitivity reactions, including maculopapular rash and SCARs, are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Delayed hypersensitivity reactions: Maculopapular reactions: Intermediate; occur 7 to 10 days after initiation. Other reactions (including SCARs): Varied; occur days to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-25340226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-25340226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between penicillins and cephalosporins and among cephalosporins is mostly related to side chain similarity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29408440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29408440'])">Ref</a></span>). A meta-analysis showed negligible cross-reactivity between penicillins and third-generation cephalosporins, such as cefdinir (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17321857']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17321857'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F147153"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (8% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum bicarbonate (≤1%), increased gamma-glutamyl transferase (1%), increased lactate dehydrogenase (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≤1%), nausea (≤3%), vomiting (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Increase in urinary protein (1% to 2%), microscopic hematuria (1%), vaginitis (≤1%), vulvovaginal candidiasis (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (≤1%), leukocyte disorder (increase or decrease in polymorphonuclear leukocytes [PMN]: ≤1%), leukocyturia (≤2%), lymphocytopenia (≤1%), lymphocytosis (≤2%), thrombocythemia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cutaneous candidiasis, maculopapular rash, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum calcium, decreased serum phosphate, glycosuria, increased serum glucose, increased serum phosphate, increased serum potassium</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, constipation, dyspepsia, flatulence, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Leukorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, decreased white blood cell count, leukocytosis, leukopenia, monocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, drowsiness, insomnia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, hyperkinetic muscle activity</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased urine specific gravity, increased blood urea nitrogen, increased urine pH, increased urine specific gravity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac failure, chest pain, hypersensitivity angiitis, hypertension, shock</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, erythema nodosum, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased amylase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute enterocolitis, bloody diarrhea, cholestasis, <i>Clostridioides difficile</i> associated diarrhea (Lv 2019), <i>Clostridioides difficile</i> colitis, hemorrhagic colitis, intestinal obstruction, melena, peptic ulcer, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation, granulocytopenia, hemolytic anemia, immune thrombocytopenia, pancytopenia, thrombocytopenia, upper gastrointestinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Fulminant hepatitis, hepatic failure, hepatitis (acute), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Serum sickness-like syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Involuntary body movements, loss of consciousness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Kimura 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory failure, eosinophilic pneumonitis, idiopathic interstitial pneumonitis, laryngeal edema, pneumonia (drug-induced), respiratory distress (feeling of suffocation), status asthmaticus</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F147166"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cefdinir, any component of the formulation, or other cephalosporins.</p></div>
<div class="block war drugH1Div" id="F147150"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Colitis: Use with caution in patients with a history of colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment (CrCl &lt;30 mL/minute); dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Iron-containing products: Cases of reddish stools have been reported with concomitant use of cefdinir and iron-containing products due to the formation of a nonabsorbable complex in the GI tract.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878371"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Iron-containing infant formulas do not affect the pharmacokinetics of cefdinir but may result in the development of red-appearing, nonbloody stools; this occurs when cefdinir is coadministered with iron-containing products and an insoluble iron-cefdinir complex forms; patients/parents should be counseled.</p></div>
<div class="block foc drugH1Div" id="F147161"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (60 mL, 100 mL); 250 mg/5 mL (60 mL, 100 mL)</p></div>
<div class="block geq drugH1Div" id="F147146"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F147168"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Cefdinir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $5.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Cefdinir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $0.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $1.65 - $1.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866230"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Omnicef: 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Omnicef: 125 mg/5 mL (60 mL, 100 mL)</p></div>
<div class="block adm drugH1Div" id="F854709"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Twice daily doses should be given every 12 hours. May be administered with or without food. Manufacturer recommends administering at least 2 hours before or after antacids or iron supplements. Shake suspension well before use.</p></div>
<div class="block admp drugH1Div" id="F52612377"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with or without food; administer with food if stomach upset occurs; administer cefdinir at least 2 hours before or after antacids or iron supplements; shake suspension well before use.</p></div>
<div class="block use drugH1Div" id="F147162"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation:</b> Treatment of acute exacerbations of chronic bronchitis in adults and adolescents caused by <i>Haemophilus influenzae</i> (including beta-lactamase-producing strains), <i>Haemophilus parainfluenzae</i> (including beta-lactamase-producing strains), <i>Streptococcus pneumoniae</i> (penicillin-susceptible strains only), and <i>Moraxella catarrhalis</i> (including beta-lactamase-producing strains)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute:</b> Treatment of acute bacterial otitis media in pediatric patients caused by <i>H. influenzae</i> (including beta-lactamase-producing strains), <i>S. pneumoniae</i> (penicillin-susceptible strains only), and <i>M. catarrhalis</i> (including beta-lactamase-producing strains)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b> Treatment of community-acquired pneumonia in adults and adolescents caused by <i>H. influenzae</i> (including beta-lactamase-producing strains), <i>H. parainfluenzae </i>(including beta-lactamase-producing strains), <i>S. pneumoniae</i> (penicillin-susceptible strains only), and <i>M. catarrhalis</i> (including beta-lactamase-producing strains)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial: </b>Treatment of acute maxillary sinusitis in adults and adolescents caused by <i>H. influenzae</i> (including beta-lactamase-producing strains), <i>S. pneumoniae</i> (penicillin-susceptible strains only), and <i>M. catarrhalis</i> (including beta-lactamase-producing strains). <b>Note:</b> According to the Infectious Diseases Society of America (IDSA) guidelines for acute bacterial rhinosinusitis, cefdinir is recommended in combination with clindamycin due to concern for pneumococcal resistance (IDSA [Chow 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infections, uncomplicated:</b> Treatment of uncomplicated skin and skin structure infections in adults, adolescents, and pediatric patients caused by <i>Staphylococcus aureus</i> (including beta-lactamase-producing strains) and <i>Streptococcus pyogenes</i>
<i>
<b>
<i>. </i></b></i>
<b>Note: </b>Cefdinir is not currently recommended in IDSA guidelines for treatment of skin and soft tissue infection; alternate agents are preferred (eg, first-generation cephalosporins) (IDSA [Stevens 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A:</b> Treatment of pharyngitis/tonsillitis in adults, adolescents, and pediatric patients caused by <i>S. pyogenes</i></p></div>
<div class="block off-label drugH1Div" id="F49249389"><span class="drugH1">Use: Off-Label: Adult</span><p>Cystitis, acute uncomplicated or acute simple cystitis; Odontogenic soft tissue infection, pyogenic</p></div>
<div class="block cyt drugH1Div" id="F13298986"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F147155"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Cefdinir. Management: Administer cefdinir 2 hours before or 2 hours after aluminum- or magnesium-containing antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron when possible. Separate doses by at least 2 hours if combined. Iron-containing infant formulas do not appear alter cefdinir pharmacokinetics, but red-appearing, non-bloody stools may develop when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Cefdinir. Specifically, Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron-containing multivitamins when possible. Separate doses by at least 2 hours if combined. Iron-containing infant formulas do not appear alter cefdinir pharmacokinetics, but red-appearing, non-bloody stools may develop<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F854704"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">An increase in most types of birth defects was not found following first trimester exposure to cephalosporins.</p></div>
<div class="block brc drugH1Div" id="F854705"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cefdinir was not detectable in breast milk following a single cefdinir 600 mg dose.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, if antibiotics are present in breast milk, nondose-related modification of bowel flora may occur. Monitor infants for GI disturbances, such as thrush and diarrhea (WHO 2002).</p></div>
<div class="block mop drugH1Div" id="F147159"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>
<div class="block pha drugH1Div" id="F147149"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F147165"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Penetrates into blister fluid, middle ear fluid, tonsils, sinus, and lung tissues.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months and Children ≤2 years: 0.67 ± 0.38 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.35 ± 0.29 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 60% to 70%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Capsule: 16% to 21%; suspension 25%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children ≤10 years: Mean range: 1.26 to 1.81 hours (Bowlware 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1.7 ± 0.6 hours with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (~12% to 18% as unchanged drug [manufacturer's labeling]; may be lower [~2.7% to 12.7%] in children ≤12 years of age [Guay 2000]).</p></div>
<div class="block phksp drugH1Div" id="F51192708"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is reduced.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC):</p>
<p style="text-indent:-2em;margin-left:8em;">Enterobacterales: Goal: 30% to 40% <i>f</i>T &gt; MIC (bacteriostatic), 60% to70% <i>f</i>T &gt; MIC (bactericidal) (Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Streptococcus </i>spp. and <i>H. influenzae</i>: Goal: &gt;40% <i>f</i>T &gt; MIC (Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug concentration in normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients: C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:10em;">7 mg/kg oral suspension, single dose: Infants ≥6 months and Children: 2.3 ± 0.65 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">14 mg/kg oral suspension, single dose:</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥6 months and Children: 3.86 ± 0.62 mg/L.</p>
<p style="text-indent:-2em;margin-left:12em;">Nonfasting: Infants ≥6 months and Children ≤10 years: 2.07 ± 1.08 mg/L (Bowlware 2006).</p>
<p style="text-indent:-2em;margin-left:12em;">Fasting: Infants ≥6 months and Children ≤10 years: 1.8 ± 1.2 mg/L (Bowlware 2006).</p>
<p style="text-indent:-2em;margin-left:10em;">25 mg/kg oral suspension, single dose:</p>
<p style="text-indent:-2em;margin-left:12em;">Nonfasting: Infants ≥6 months and Children ≤10 years: 3.7 ± 1.45 mg/L (Bowlware 2006).</p>
<p style="text-indent:-2em;margin-left:12em;">Fasting: Infants ≥6 months and Children ≤10 years: 4.42 ± 2.58 mg/L (Bowlware 2006).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:10em;">300 mg oral capsule, single dose: 1.6 ± 0.55 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">600 mg oral capsule, single dose: 2.87 ± 1.01 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect:</i> Generally &lt;1 hour; varies based on organism (Craig 1991; Craig 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F147169"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Iconir | Minocet | Omnicef | Sefarin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cednir | Cefdir | Cefexta | Cefida</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Celofarm</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cefzon | Heng dan | Quan ze fu | Shi fu ni | Te pu kang | Yi bei di</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cefdial</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Kefnir</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cedenir | Cefathird | Cefdin | Denrocef | Dinar | Egynir | Maxdinir | Merbactadin | Omnicef | Rame dinir | Spectracefocure</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Sefarin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Nircef | Omnicef</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adcef | Aldinir | Biocef | Cednir | Cefdiel | Cefrine | Entra | Kefdure | Kefnir | Maxicef-o | Oceph | Resdinir | Rtist | Safedinir | Sefdin | Zefdinir</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Cefdinisam</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Dinixir | Iconir | Omnicef | Sefarin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ceflosil | Cefnil | Cefzon</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Akudinir | Aldinir | Labnir | Rtist</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anycef | Bycef | Cefdana | Cefdiar | Cefdier | Ckd cefdinir | Dinicef | Hidinol | Omacef | Omnicef | Omnicef fine granule for children | Optir</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Minocet | Omnicef</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Minocet | Sefarin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Emmit | Omnicef r</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cefdiel | Kefnir</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Kefnir</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cefnaxl | Nirocef | Omicef | Omnicef | Onicef | Orcef ds | Safdicure | Sefdy | Trinir</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cefanir | Cefdin | Cefnir | Denar | Dinacor | Efdir | Fendinir | Mcnir | Mednir | Nifrose | Nifrose ds | Rinidef | Solinir | Solinir ds | Steadier</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Omnicef | Omnicef Omni-Pac</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Azord | Omnicef | Sefarin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Denacif | Minocet | Omnicef | Sefarix | Xevaneer</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Omnicef</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dinicef | Omnicef | Samnir</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Asemax | Cefbir | Cefdifix | Cefnet | Ceftinex | Cempes | Clasem | Elucef | Encef | Menacef | Nuax | Rodinir | Sefpen | Tricef</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">3 Dinir | Rodinir</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cefdial</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Anbilid | Bostocef | Bravine | Cadicefdin | Danircap | Dentimex | Docefnir | Francefdi | Haginir | Midaxin | Newcefdin | Rinedif | Tabracef | Tiphanicef | Topdinir | Trikadinir | Uscefdin | Zebacef</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17878469">
<a name="17878469"></a>Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. <i>Proc Am Thorac Soc</i>. 2007;4(7):554-564.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/17878469/pubmed" id="17878469" target="_blank">17878469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15361722">
<a name="15361722"></a>Block SL, Busman TA, Paris MM, Bukofzer S. Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media. <i>Pediatr Infect Dis J</i>. 2004;23(9):834-838. doi:10.1097/01.inf.0000137574.28711.c4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/15361722/pubmed" id="15361722" target="_blank">15361722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16117986">
<a name="16117986"></a>Block SL, Cifaldi M, Gu Y, Paris MM. A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study. <i>Clin Ther</i>. 2005;27(6):786-794. doi:10.1016/j.clinthera.2005.06.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/16117986/pubmed" id="16117986" target="_blank">16117986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16511381">
<a name="16511381"></a>Bowlware KL, McCracken GH Jr, Lozano-Hernandez J, Ghaffar F. Cefdinir pharmacokinetics and tolerability in children receiving 25 mg/kg once daily. <i>Pediatr Infect Dis J</i>. 2006;25(3):208-210. doi:10.1097/01.inf.0000202210.22512.88<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/16511381/pubmed" id="16511381" target="_blank">16511381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>, 2011, 53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23039319">
<a name="23039319"></a>Casey JR, Block SL, Hedrick J, Almudevar A, Pichichero ME. Comparison of amoxicillin/clavulanic acid high dose with cefdinir in the treatment of acute otitis media. <i>Drugs</i>. 2012;72(15):1991-1997. doi:10.2165/11590320-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/23039319/pubmed" id="23039319" target="_blank">23039319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BluePoint.1">
<a name="BluePoint.1"></a>Cefdinir capsules [prescribing information]. BluePoint Laboratories; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ascend.1">
<a name="Ascend.1"></a>Cefdinir capsules [prescribing information]. Parsippany, NJ: Ascend Laboratories, LLC; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lupin.1">
<a name="Lupin.1"></a>Cefdinir for oral suspension [prescribing information]. Baltimore, MD; Lupin Pharmaceuticals Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ascend.2">
<a name="Ascend.2"></a>Cefdinir for oral suspension [prescribing information]. Parsippany, NJ: Ascend Laboratories, LLC; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention. FAQs for clinicians about <i>C. diff</i>. Updated July 20, 2021. Accessed September 28, 2021. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chow.2019">
<a name="Chow.2019"></a>Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.<i> Clin Infect Dis.</i> 1998;26(1):1-10. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1991">
<a name="Craig.1991"></a>Craig WA. The postantibiotic effect. <i>Clin Microbiology Newsletter.</i> 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2663814">
<a name="2663814"></a>de Lalla F, Privitera G, Ortisi G, et al. Third generation cephalosporins as a risk factor for <i>Clostridium difficile</i>-associated disease: a four-year survey in a general hospital. <i>J Antimicrob Chemother</i>. 1989;23(4):623-631. doi:10.1093/jac/23.4.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/2663814/pubmed" id="2663814" target="_blank">2663814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/wp-content/uploads/2023/01/GOLD-2023-ver-1.2-7Jan2023_WMV.pdf. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.2013">
<a name="Golightly.2013"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys</i>. Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11144395">
<a name="11144395"></a>Guay DR. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. <i>Pediatr Infect Dis J</i>. 2000;19(12 Suppl):S141-S146. doi:10.1097/00006454-200012001-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/11144395/pubmed" id="11144395" target="_blank">11144395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
<span class="doi">10.1093/cid/ciq257</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9210677">
<a name="9210677"></a>Gwaltney JM Jr, Savolainen S, Rivas P, et al. Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group. <i>Antimicrob Agents Chemother</i>. 1997;41(7):1517-1520. doi:10.1128/AAC.41.7.1517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/9210677/pubmed" id="9210677" target="_blank">9210677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17292580">
<a name="17292580"></a>Hadley JA, Pfaller MA. Oral beta-lactams in the treatment of acute bacterial rhinosinusitis. <i>Diagn Microbiol Infect Dis</i>. 2007;57(3 suppl):S47-S54. doi:10.1016/j.diagmicrobio.2006.11.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/17292580/pubmed" id="17292580" target="_blank">17292580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med</i>. 2016;164(6):425-434. doi: 10.7326/M15-1840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15823766">
<a name="15823766"></a>Henry DC, Kapral D, Busman TA, Paris MM. Cefdinir versus levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology: a multicenter, randomized, double-blind study. <i>Clin Ther</i>. 2004;26(12):2026-2033. doi:10.1016/j.clinthera.2004.12.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/15823766/pubmed" id="15823766" target="_blank">15823766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9661010">
<a name="9661010"></a>Hishida A, Ohishi K, Nagashima S, Kanamaru M, Obara M, Kitada A. Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. <i>Antimicrob Agents Chemother.</i> 1998;42(7):1718-1721. doi:10.1128/AAC.42.7.1718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/9661010/pubmed" id="9661010" target="_blank">9661010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28002709">
<a name="28002709"></a>Hoberman A, Paradise JL, Rockette HE, et al. Shortened antimicrobial treatment for acute otitis media in young children. <i>N Engl J Med</i>. 2016;375(25):2446-2456. doi:10.1056/NEJMoa1606043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/28002709/pubmed" id="28002709" target="_blank">28002709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11300142">
<a name="11300142"></a>Kimura Y, Kawamura M, Owada M, Fujiwara T, Maesawa C, Hiramori K. Successful steroid therapy for cefdinir-induced acute tubulointerstitial nephritis with progressive renal failure. <i>Intern Med</i>. 2001;40(2):114-117. doi:10.2169/internalmedicine.40.114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/11300142/pubmed" id="11300142" target="_blank">11300142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11144402">
<a name="11144402"></a>Klein JO and McCracken GH Jr, “Summary: Role of a New Oral Cephalosporin, Cefdinir, for Therapy of Infections of Infants and Children,” <i>Pediatr Infect Dis J</i>, 2000, 19(12 Suppl):S181-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/11144402/pubmed" id="11144402" target="_blank">11144402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824827">
<a name="20824827"></a>Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. <i>Cochrane Database Syst Rev</i>. 2010;2010(9):CD001095. doi:10.1002/14651858.CD001095.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/20824827/pubmed" id="20824827" target="_blank">20824827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al, "The Diagnosis and Management of Acute Otitis Media," <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Limb.2021">
<a name="Limb.2021"></a>Limb CJ, Lustig LR, Durand M. Acute otitis media in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30020891">
<a name="30020891"></a>Litao G, Jingjing S, Yu L, Lei Z, Xiaona H, Zhijing Z. Risk factors for antibiotic-associated diarrhea in critically ill patients. <i>Med Sci Monit</i>. 2018;24:5000-5007. doi:10.12659/MSM.911308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/30020891/pubmed" id="30020891" target="_blank">30020891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30921218">
<a name="30921218"></a>Lv X, Zhang J, Jiang M, Liu Y, Ren W, Fang Z. <i>Clostridium difficile</i>-associated diarrhea following the therapy with antibiotic and proton pump inhibitors in a 77-year-old man with several comorbidities: a case report. <i>Medicine (Baltimore)</i>. 2019;98(13):e15004. doi:10.1097/MD.0000000000015004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/30921218/pubmed" id="30921218" target="_blank">30921218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31118710">
<a name="31118710"></a>Ma H, Zhang L, Zhang Y, Liu Y, He Y, Guo L. Combined administration of antibiotics increases the incidence of antibiotic-associated diarrhea in critically ill patients. <i>Infect Drug Resist</i>. 2019;12:1047-1054. doi:10.2147/IDR.S194715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/31118710/pubmed" id="31118710" target="_blank">31118710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31876601">
<a name="31876601"></a>Marchisio P, Galli L, Bortone B, et al. Updated guidelines for the management of acute otitis media in children by the Italian Society of Pediatrics: treatment. <i>Pediatr Infect Dis J</i>. 2019;38(12S suppl):S10-S21. doi:10.1097/INF.0000000000002452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/31876601/pubmed" id="31876601" target="_blank">31876601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27003987">
<a name="27003987"></a>McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and <i>Clostridium difficile</i> infections. <i>World J Gastroenterol</i>. 2016;22(11):3078-3104. doi:10.3748/wjg.v22.i11.3078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/27003987/pubmed" id="27003987" target="_blank">27003987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Respir Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29408016">
<a name="29408016"></a>Nasiri MJ, Goudarzi M, Hajikhani B, Ghazi M, Goudarzi H, Pouriran R. <i>Clostridioides (Clostridium) difficile</i> infection in hospitalized patients with antibiotic-associated diarrhea: a systematic review and meta-analysis. <i>Anaerobe</i>. 2018;50:32-37. doi:10.1016/j.anaerobe.2018.01.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/29408016/pubmed" id="29408016" target="_blank">29408016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25340226">
<a name="25340226"></a>National Clinical Guideline Centre (UK). <i>Drug Allergy: Diagnosis and Management of Drug Allergy in Adults, Children and Young People</i>. London: National Institute for Health and Care Excellence (UK); September 2014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/25340226/pubmed" id="25340226" target="_blank">25340226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Otitis media (acute): antimicrobial prescribing. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng91. Published March 2018. Accessed November 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24187143">
<a name="24187143"></a>Parker S, Mitchell M, Child J. Cephem antibiotics: wise use today preserves cure for tomorrow. <i>Pediatr Rev</i>. 2013;34(11):510-524. doi:10.1542/pir.34-11-510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/24187143/pubmed" id="24187143" target="_blank">24187143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patel.2021">
<a name="Patel.2021"></a>Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17385141">
<a name="17385141"></a>Peled N, Pitlik S, Samra Z, Kazakov A, Bloch Y, Bishara J. Predicting <i>Clostridium difficile</i> toxin in hospitalized patients with antibiotic-associated diarrhea. <i>Infect Control Hosp Epidemiol</i>. 2007;28(4):377-381. doi:10.1086/513723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/17385141/pubmed" id="17385141" target="_blank">17385141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15212560">
<a name="15212560"></a>Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. <i>Drugs</i>. 2004;64(13):1433-1464. doi:10.2165/00003495-200464130-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/15212560/pubmed" id="15212560" target="_blank">15212560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pichichero.2018">
<a name="Pichichero.2018"></a>Pichichero ME. Treatment and prevention of streptococcal pharyngitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17908614">
<a name="17908614"></a>Pichichero ME, Casey JR. Bacterial eradication rates with shortened courses of 2nd- and 3rd-generation cephalosporins versus 10 days of penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. <i>Diagn Microbiol Infect Dis</i>. 2007;59(2):127-130. doi:10.1016/j.diagmicrobio.2007.04.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/17908614/pubmed" id="17908614" target="_blank">17908614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17321857">
<a name="17321857"></a>Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. <i>Otolaryngol Head Neck Surg</i>. 2007;136(3):340-347. doi:10.1016/j.otohns.2006.10.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/17321857/pubmed" id="17321857" target="_blank">17321857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11144400">
<a name="11144400"></a>Pichichero ME, Gooch WM 3rd. Comparison of cefdinir and penicillin V in the treatment of pediatric streptococcal tonsillopharyngitis. <i>Pediatr Infect Dis J</i>. 2000;19(12)(suppl):S171-S173. doi:10.1097/00006454-200012001-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/11144400/pubmed" id="11144400" target="_blank">11144400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29408440">
<a name="29408440"></a>Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quaratino D, Gaeta F. Cross-reactivity and tolerability of cephalosporins in patients with IgE-mediated hypersensitivity to penicillins. <i>J Allergy Clin Immunol Pract</i>. 2018;6(5):1662-1672. doi:10.1016/j.jaip.2018.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/29408440/pubmed" id="29408440" target="_blank">29408440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2 Suppl):S1-S39. doi: 10.1177/0194599815572097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11557496">
<a name="11557496"></a>Ross GH, Hovde LB, Ibrahim KH, Ibrahim YH, Rotschafer JC. Comparison of once-daily versus twice-daily administration of cefdinir against typical bacterial respiratory tract pathogens. <i>Antimicrob Agents Chemother</i>. 2001;45(10):2936-2938. doi:10.1128/AAC.45.10.2936-2938.2001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/11557496/pubmed" id="11557496" target="_blank">11557496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.2022">
<a name="Sethi.2022"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23091044">
<a name="23091044"></a>Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2012;55(10):1279-1282. doi:10.1093/cid/cis847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/23091044/pubmed" id="23091044" target="_blank">23091044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21653301">
<a name="21653301"></a>Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of <i>Clostridium difficile</i> infection. <i>Clin Infect Dis</i>. 2011;53(1):42-48. doi:10.1093/cid/cir301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/21653301/pubmed" id="21653301" target="_blank">21653301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9748717">
<a name="9748717"></a>Tomino Y, Fukui M, Hamada C, Inoue S, Osada S. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis. <i>Arzneimittelforschung</i>. 1998;48(8):862-867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/9748717/pubmed" id="9748717" target="_blank">9748717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12827001">
<a name="12827001"></a>Turck D, Bernet JP, Marx J, et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. <i>J Pediatr Gastroenterol Nutr</i>. 2003;37(1):22-26. doi:10.1097/00005176-200307000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/12827001/pubmed" id="12827001" target="_blank">12827001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams.<i> Clin Infect Dis</i>. 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23796742">
<a name="23796742"></a>Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. <i>Pediatrics</i>. 2013;132(1):e262-e280. doi:10.1542/peds.2013-1071<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/23796742/pubmed" id="23796742" target="_blank">23796742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. <i>Clin Infect Dis</i>. 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32518780">
<a name="32518780"></a>Zhou H, Xu Q, Liu Y, Guo LT. Risk factors, incidence, and morbidity associated with antibiotic-associated diarrhea in intensive care unit patients receiving antibiotic monotherapy. <i>World J Clin Cases</i>. 2020;8(10):1908-1915. doi:10.12998/wjcc.v8.i10.1908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefdinir-drug-information/abstract-text/32518780/pubmed" id="32518780" target="_blank">32518780</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8602 Version 411.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
